Close menu




July 12th, 2021 | 10:07 CEST

CureVac, XPhyto Therapeutics, Paion - Where are the turning points?

  • Biotechnology
Photo credits: pixabay.com

"Opportunity and risk are two sides of the same coin", that is to say, with great potential returns, there is also the risk of incurring significant price losses. The biotechnology sector, in particular, offers investors a broad universe in which to find lucrative investments. We present three exciting ideas below. Who is winning the race?

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: CUREVAC N.V. O.N. | NL0015436031 , XPHYTO THERAPEUTICS | CA98421R1055 , PAION O.N | DE000A0B65S3

Table of contents:


    CUREVAC NV - Hope dies last

    It was not long ago that German biotech company CureVac reported the efficacy of its Corona vaccine candidate. A preliminary evaluation of the preparation had indicated efficacy of around 48%. This value has now been finally confirmed. It is a minor catastrophe. Not only is the efficacy significantly lower than that of the competitor products, but the absolute value is also poor, even if some experts try to put this into perspective.

    CureVac is currently lagging behind Astra Zeneca, BioNTech/Pfizer, Moderna and Johnson & Johnson. Success is also becoming more difficult due to the ever-increasing number of mutations. The federal government has now announced that it will no longer include a CureVac vaccine in the vaccination campaign. CureVac, like BioNTech and Moderna, relies on mRNA technology, but takes a slightly different approach. Whether this approach has ultimately failed or is permanently inferior to the mRNA technology of BioNTech or Moderna cannot be conclusively assessed at this point.

    The German government, which has invested EUR 300 million in CureVac via the development bank KfW and holds a 16% stake, is probably not quite so pleased about the developments. At a price of around EUR 49, the Company is valued at just under EUR 9 billion. Not much has been heard from analysts yet. The experts are probably still busy calculating what the Company is now worth after the severe setback. And it would not be surprising if the experts' opinions differ widely. It remains exciting.

    XPHYTO THERAPEUTICS CORP - Innovative and fast

    The Canadian Company focuses on accelerating new and innovative medical solutions. Very roughly, the fields include drug formulations, diagnostics, drug delivery and neurological medications. Among other things, the Company specializes in clinical validation and cannabis growth markets in Europe. In addition to testing kits, XPhyto offers solutions to help the human body better absorb medical agents, such as patches, and develops medicines. In addition to a neurological drug, the Canadians are also working with psychedelic agents.

    But the Company also provides innovative answers in Corona times. XPhyto has developed a method that allows PCR tests to deliver meaningful results within 20 to 25 minutes. The Company thus scores points for speed. Given the upcoming wave of travel, XPhyto's solution could make the cash register ring.

    At the end of Q2, the Canadians reached an agreement with ten testing centers. XPhyto then signed a contract with ten Covid-19 test centers and the first 1,000 Covid-ID Labs (tests) are already in delivery to test centers in Berlin. The test is predestined for airports, clinics, resorts, etc. XPhyto's solution offers a viable approach with timely results - hence high revenue potential for the Company. The Company remains relatively unspecific regarding an outlook but intends to make up for this once the PCR business is up and running.

    PAION AG - Good news from China

    Paion is also active in an exciting field. The Aachen-based company aims to become a leading specialty pharma company in anesthesia and intensive care by bringing novel products to the market. The activities revolve around innovative active ingredients for outpatient and hospital sedation, anesthesia and intensive care medicine. The lead substance is Remimazolam, an intravenously administered, ultra-short-acting and easily controlled benzodiazepine sedative and anesthetic.

    Remimazolam is partnered in several markets outside Europe. The drug is approved for short sedation in the US and EU and for general anesthesia in Japan, South Korea and perhaps soon in China. Recently, the Company announced that its Chinese Remimazolam licensee, Yichang Humanwell, had informed Paion that the Chinese National Medical Products Administration (NMPA) had accepted the marketing authorization application for Remimazolam Besylate in general anesthesia for review. Should further progress be made here, this should certainly have a positive effect on the share price. Currently, the shares are trading at EUR 1.90, valuing the Company at EUR 135 million.


    Ultimately, it is always a good idea for investors to build up a diversified portfolio. Then, by spreading the risk, the potential of exciting stocks like XPhyto or Paion can be captured, and the sleepless nights are minimized.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST

    Evotec, Defence Therapeutics, Formycon - Biotech opportunity!

    • Biotechnology

    Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.

    Read